EGFR and non-small cell lung carcinoma: The emergence of drug resistance to EGFR TKIs remains a major obstacle to the successful treatment of relevant malignancies including NSCLC, often leading to poor patient prognosis.[8a] In the current study, we identified that CMTM6 acts as a stabilizer of EGFR in endocytic trafficking.